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Abstract
Background: Administration of exogenous corticosterone is an effective preclinical model of depression, but its
use has involved primarily adult rodents. Using two different procedures of administration drawn from the
literature, we explored the possibility of exogenous corticosterone models in adolescence, a time of heightened
risk for mood disorders in humans.
Methods: In experiment 1, rats were injected with 40 mg/kg corticosterone or vehicle from postnatal days 30 to
45 and compared with no injection controls on behavior in the elevated plus maze (EPM) and the forced swim
test (FST). Experiment 2 consisted of three treatments administered to rats from postnatal days 30 to 45 or as
adults (days 70 to 85): either corticosterone (400 μg/ml) administered in the drinking water along with 2.5%
ethanol, 2.5% ethanol or water only. In addition to testing on EPM, blood samples after the FST were obtained to
measure plasma corticosterone. Analysis of variance (ANOVA) and alpha level of P < 0.05 were used to determine
statistical significance.
Results: In experiment 1, corticosterone treatment of adolescent rats increased anxiety in the EPM and decreased
immobility in the FST compared to no injection control rats. However, vehicle injected rats were similar to
corticosterone injected rats, suggesting that adolescent rats may be highly vulnerable to stress of injection. In
experiment 2, the intake of treated water, and thus doses delivered, differed for adolescents and adults, but there
were no effects of treatment on behavior in the EPM or FST. Rats that had ingested corticosterone had reduced
corticosterone release after the FST. Ethanol vehicle also affected corticosterone release compared to those
ingesting water only, but differently for adolescents than for adults.
Conclusions: The results indicate that several challenges must be overcome before the exogenous corticosterone
model can be used effectively in adolescents.
Background
The World Health Organization has found mood disor-
ders such as anxiety and depression to be a major con-
tributor to disability and loss of years of health in
women and in men [1]. Stressful experiences are impli-
cated in the pathogenesis of mood disorders, and dysre-
gulation of the hypothalamic-pituitary-adrenal (HPA)
axis is a key feature of depression in particular (reviewed
in [2-6]). Clinical research indicates that adolescence is a
time of increased risk for mood disorders (reviewed in
[7,8]). Changes in the reactivity of the stress systems
during times of biological transitions, such as those
occurring in the nervous system and gonadal systems
during adolescence, are proposed to underlie the
increased vulnerability [9].
The use of animal models, though not without limita-
tions, is recognized as an important approach to under-
standing mood disorders [10,11]. Animal models of
depression based on environmental stress (repeated
* Correspondence: cmccormick@brocku.ca
Department of Psychology and Centre for Neuroscience, Brock University, St
Catharines, Ontario, Canada
Waters and McCormick Biology of Mood & Anxiety Disorders 2011, 1:4
http://www.biolmoodanxietydisord.com/content/1/1/4 Biology of 
Mood & Anxiety Disorders
© 2011 Waters and McCormick; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.stress exposures administered by the experimenter) have
high face and construct validity [12]. Until recently,
however, the focus has been on stressors in perinatal life
or in adulthood rather than in adolescence [13]. Limita-
tions of many animal models of environmental stress
include the lack of control over individual differences
and variation in procedures from laboratory to labora-
tory, which lead to inconsistencies in the literature
(reviewed in [14,15]). These limitations may be espe-
cially relevant in investigations of adolescent rats, given
the sensitivity of gonadal maturation to environmental
factors, the ongoing development of the HPA axis, and
the relatively short time frame in which adolescent
development occurs [13]. One classification system for
adolescence (a transitional period with no clear ‘onset’
or ‘offset’) involves three stages, a prepubescence/early
adolescence period from postnatal days 21 (when rats
are typically weaned in the laboratory) to 34, a mid-ado-
lescence period from postnatal days 34 to 46 (time in
which most rats first exhibit the physical markers of
puberty, such as vaginal opening and balanopreputial
separation), and a late adolescence period from postna-
tal days 46 to 59 [16-18].
The effects of chronic or repeated stress in humans
and in animal models are mediated primarily by the
prolonged elevations of glucocorticoids (cortisol in
humans, corticosterone in rodents) that are the end-
point of activation of the HPA axis [19,20]. Thus,
repeated administration of exogenous corticosterone
h a sb e e np r o p o s e da sa ne f f e c t i v em e a n so fc i r c u m -
venting some of the limitations of animal models of
chronic stress exposures (reviewed in [14]). Although
there is much evidence to indicate that repeated treat-
ment with corticosterone produces reliable changes in
a variety of depressive-like behaviors (reviewed in
[14]), this approach has yet to be explored in adoles-
cence. One exception is a study of a low dose of corti-
costerone (20 mg/ml) administered in the drinking
water for 2 months (early adolescence into adulthood),
which was found to decrease depression-like behavior
in male mice [21]. Thus, more studies are required to
assess the use of exogenous corticosterone as an ani-
mal model using higher doses and within a timeframe
limited to adolescence.
Our laboratory has used a social instability stress
model in rats to investigate the consequences of expo-
sure to stressors in mid-adolescence (daily 1 h isolation
and change of cage partner from postnatal days 30 to
45) (reviewed in [22]). Although social instability stress
in adolescence produces lasting changes in neurogenesis
and decrements in performance of hippocampal-depen-
dent tasks (for example, [23,24]), effects on anxiety-like
and depressive behavior have been modest [25,26], per-
haps because of habituation of corticosterone release to
the repeated stress procedures in male rats [27]. Thus,
in the present experiments, we investigated the effects
of repeated administration of exogenous corticosterone
over the same timeframe as our adolescent social
instability procedure on anxiety-like and depressive
behavior. In experiment 1, we used a 40 mg/kg injection
of corticosterone and in experiment 2 we used a 400
mg/ml dose administered in the drinking water; both
doses and administration procedures have been used
extensively with adult rats (for example, injection
[28-30] and in water [31-33]). Vehicle and no treatment
controls were included in both experiments, and an
adult treatment comparison group was included in
experiment 2. In both experiments, 24 h after the last
treatment day, anxiety-like behavior was evaluated using
the elevated plus maze and after another 24 h, depres-
sive behavior was evaluated using the forced swim test,
both well validated measures (reviewed in [34,35]). In
experiment 2, blood samples were obtained at time-
points after the end of the forced swim test to evaluate
treatment effects on stress-induced corticosterone
release. The aim of the experiments was to assess the
potential of exogenous corticosterone as a model for
adolescent mood disorders. The main hypothesis of
both experiments was that chronic treatment with exo-
genous corticosterone in adolescence would increase
anxiety-like and depressive behavior in rats.
Methods
Experiment 1
Animals
Male Long-Evans rats (n = 24) were obtained from
Charles River (St Constant, Quebec, Canada) at 22 days
of age. Rats were housed in pairs in polycarbonate cages
and were provided with a plastic tube in each cage for
enrichment throughout the experiment. Rats were iden-
tified by tail coloring with a felt tip marker. The rats
were kept on a 12 h light, 12 h dark light cycle, and
were given unlimited access to rat chow and water. All
experimental procedures were consistent with National
Institutes of Health Guide for Care and Use of Labora-
tory Animals (Publication No. 85-23, revised 1985), and
Canadian Council on Animal Care guidelines and were
approved by the Brock University Institutional Animal
Care and Use Committee.
Treatment
Starting on postnatal day 30, rats were randomly
assigned to one of three treatment conditions. The
CORT group (n = 8) was given a daily injection subcu-
taneously for 16 days of 40 mg/kg/ml corticosterone
(Steraloids, Newport, RI, USA) (procedure as in [36,37])
suspended in isotonic saline and 2% Tween 80 (Sigma-
Aldrich, St Louis, MO, USA). The VEHIC group (n = 8)
was injected daily with vehicle for 16 days. After
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each pair of rats that shared a cage was administered
the same treatment. Previous research has found this
dose of corticosterone injection to produce plasma cor-
ticosterone levels of approximately 2,100 ng/ml 1-4 h
after the injection [37]. The rats were weighed once
every 3 days, and the injection volume was adjusted
accordingly. The NO-INJ (no injection, n = 8) control
group was not disturbed except for cage maintenance
and was weighed only on postnatal days 30 and 45 (first
and last injection days). Rats were tested in the elevated
plus maze on postnatal day 46 and in the forced swim
test on postnatal day 47.
Elevated plus maze
The elevated plus maze (EPM), first described by Pellow
and colleagues [38], is a well validated measure of anxi-
ety in rodents [34]. The EPM relies on conflict between
the propensity of rodents to explore novel territory and
their fear of open and elevated areas. The EPM con-
sisted of four arms 50 cm in length, and walls enclosing
two arms (closed arms) 42 cm in height constructed out
of grey painted plywood. The sides of the open arms
had 1.3 cm high ledges. The maze was raised 79 cm off
the ground and was kept in a separate room from the
colony. During testing, the maze was illuminated with
dim white light and white noise (approximately 60 dB)
was played. Each rat was placed in the closed arm at the
end farthest from the center and was allowed to explore
the maze for 5 min. All sessions were videotaped, and
tapes were later scored while blind to treatment condi-
tion. Tapes were scored for time spent in the open arm
(with more time on the open arm, higher percent time
on open arm, and higher percentage of open arm entries
all indicative of less anxiety) and center hub as well as
the total number of entries into closed arms (used as an
index of locomotor activity), rears (when the rat stands
on its hind legs) and head dips (when the rat reaches its
head over the edge of the open arm). Rears and dips are
considered measures of exploratory behavior that are
exhibited more when less anxious.
Forced swim test
The forced swim test (FST) is a measure of behavioral
d e s p a i r( f o re x a m p l e ,[ 3 9 ] )a n dc o n s i s t e do fac l e a r
cylinder 20.3 cm in diameter filled 24.1 cm high with
water such that a rat was unable to touch the bottom or
c l i m bo v e rt h es i d e .T h ew a t e rw a sw a r m e dt o2 6 ° C ,
and it was changed for each rat. Rats were placed in the
water and left in the tank for 15 min in experiment 1
and 20 min in experiment 2 (longer time in experiment
2 was used for maximal corticosterone release). All ses-
sions were videotaped, and tapes were later scored while
blind to treatment condition. Behavioral measures for
analysis were derived from the literature (for example,
[40,41]) and included the following four behaviors:
swimming (quick movements of forelimbs and/or hin-
dlimbs, including swimming in circles and pedaling),
climbing (in a vertical position, pawing at the side of the
cylinder with front paws and leveraging the body slightly
out of the water), diving (head under water, swimming
to the bottom of cylinder, including circling at the bot-
tom) and immobility (reduced movement including
floating and slow circling or pedaling). Diving occurred
with very low frequency, and was thus not included in
statistical analyses. Climbing reflects the most vigorous
attempt at escape whereas immobility is the measure
considered to represent depressive-like behavior.
Classically the FST is administered in two sessions
that are 24 h apart, with latency to immobility and time
spent immobile measured in the second session and the
first session considered the means to induce a depres-
sive state (for example, [39]). However, stressors or
chronic manipulations are found to produce depression-
like states and thus differences among groups can be
found in the first session (for example, [28,36,42]).
Further, the effects of chronic corticosterone treatment
for 21 days in adults were the same whether tested with
a1d a yv e r s i o no ft h et e s to ra2d a yv e r s i o n[ 2 9 ] .
Therefore, the experiments described here used a one-
session test.
Experiment 2
Animals, treatment, and procedure
Male Long-Evans rats were obtained from Charles River
at 22 days of age (n = 20) or at 64 days of age (n = 20)
and were housed in age-matched pairs as in experiment
1. Starting on postnatal day 30 or 70, the drinking water
was replaced for the CORT-ETOH rats (n = 8 per age
group) with a solution of 400 μg/ml corticosterone
(Steraloids) dissolved in 2.5% ethanol. To ensure that
any effects observed were the result of corticosterone
treatment and not ethanol exposure, a second group
was given 2.5% ethanol to drink (ETOH rats, n = 6 per
group). The WATER rats (n = 6 per group) continued
to receive tap water. Each solution was colored with a
different food coloring to be easily distinguished from
one another. After 16 days, on postnatal day 46 or 86,
treatment was removed and tap water was provided to
all. During treatment, the mass of water consumed was
measured every 2 days. Rats were weighed before and
after the 16 days of treatment, but were not handled
during the course of treatment, except for cage cleaning
thrice weekly. Using weight at the start and end of treat-
ment, the dose of ethanol and of corticosterone con-
sumed by the pair of rats in a cage over a 2 day period
was calculated. To calculate the doses of ethanol and
corticosterone, the density of each solution was deter-
mined by weighing 1 ml of each solution, because con-
sumption was measured in mass. Using the beginning
Waters and McCormick Biology of Mood & Anxiety Disorders 2011, 1:4
http://www.biolmoodanxietydisord.com/content/1/1/4
Page 3 of 13and ending weights, the approximate weight on day 8 of
treatment was extrapolated, and the ethanol and corti-
costerone doses for days 7 and 8 were calculated based
on this weight. All rats in this experiment were tested
on the EPM on either postnatal day 46 or 47 and on the
F S To np o s t n a t a ld a y4 7o r8 7u s i n gt h em e t h o d s
described for experiment 1.
Collection and measurement of plasma corticosterone
To determine the amount of corticosterone released
after the FST, blood was collected by tail nick from each
rat immediately, 45 min and 90 min after removal from
the test. No baseline was obtained before the FST in
order that behavior in the FST would not be affected by
the blood sampling. Blood samples were centrifuged at
3,000 rpm and 4°C for 20 min. Plasma was collected
and stored at -20°C until corticosterone was measured
using enzyme-linked immunosorbent assay kits (Neogen,
Lansing, MI, USA). Corticosterone was extracted from
the samples using ethyl ether and the samples were
reconstituted in a buffer provided in the kit. The assay
was run entirely as specified in the instructions for the
kit, except that the reconstituted samples were diluted
twofold compared to the kit instructions in order for
the stress levels of corticosterone to be readable within
the standard curve. The minimum detection level for
the assay is 1 μg per tube. The antiserum crossreacts
with deoxycorticosterone (38%), and only slightly with
cortisol (1.1%), testosterone (0.12%), and estradiol
(<0.01%). The intra-assay and interassay reliabilities
were both less than 10%.
Results and discussion
Experiment 1
Weight
There were no group differences in weight on postnatal
day 30 (F1,21 = 0.02, P = 0.93), but by postnatal day 45,
corticosterone injected (CORT) rats weighed less than
vehicle injected (VEHIC) and no injection (NO-INJ) rats
(F1,21 = 10.78, P = 0.001, see Figure 1). The finding of
reduced weight gain of CORT rats is consistent with the
evidence of reduced weight gain or weight loss after
exogenous corticosterone treatment in adult rats (for
example, [28,36]) and after chronic stressors in adoles-
cent and in adult rats (for example, [43-45]).
EPM
Although vehicle injection had no effect on weight gain,
both VEHIC and CORT treated rats had increased anxi-
ety-like behavior compared to NO-INJ rats. NO-INJ rats
s p e n tm o r et i m eo nt h eo p e na r m( F 1,21 =7 . 9 6 ,P =
0.003, see Figure 2) than did VEHIC (P = 0.002) and
CORT (P = 0.002) rats, which did not differ (P = 0.78).
The same pattern of significant differences as time in
the open arm were obtained for the percentage of time
i nt h eo p e na r mu s i n gt i m ei no p e na n dc l o s e da r m s
without time in the hub as a denominator (F1,21 =7 . 9 6 ,
P = 0.003, (mean, ± SEM) = VEHIC rats (6.4%, ± 2.6),
CORT rats (7.6%, ± 1.6), and NO-INJ rats (23.7%, ±
5.0)). Differences were less marked using percentage of
open arm entries relative to total arm entries as the
index of anxiety (F1,21 = 3.65, P =0 . 0 4 5 ,w i t ho n l y
VEHIC rats having a lower percentage of open arm
entries (20.8%, ± 6.8) than NO-INJ rats (37.7%, ± 2.75),
and neither group different from CORT rats (29.8%, ±
1.9)). NO-INJ rats reared and head dipped more than
did VEHIC and CORT rats, which did not differ (F1,21 =
32.45, P < 0.0001, F1,21 =1 0 . 4 1 ,P < 0.0001, F1,21 = 4.76,
P =0 . 0 2 ,s e eF i g u r e2 ) .T h ed i f f e r e n c e sa m o n gt h e
groups in time spent in the hub of the EPM and the
number of closed arm entries were not significant (F1,21
= 2.72, P = 0.09 and F1,21 = 3.11, P = 0.07).
Figure 1 Mean (SEM) weight at postnatal day 30 (P30) and
P45, the first and last day of treatment for the corticosterone
injected (CORT), vehicle injected (VEHIC) and no injection (NO-
INJ) groups. Matched letters indicate significant (P < 0.05)
differences between groups.
Figure 2 Mean (SEM) of the behavioral measures for the
elevated plus maze (EPM) for corticosterone injected (CORT),
vehicle injected (VEHIC) and no injection (NO-INJ) groups.
Matched letters indicate significant (P < 0.05) differences between
groups within each behavioral measure.
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cient in adolescence to increase anxiety-like behavior.
Although acute injections are known to be a mild stres-
sor (for example, [46]), adult rodents readily habituate
to repeated injections (for example, [47,48]). Further, in
studies of adults, even when a higher number of injec-
tions were used than the 16 used here, differences are
observed between vehicle-treated and corticosterone-
treated groups [28,29,36,49]. Thus, adolescents may be
more sensitive to injection stress than are adults.
FST
There was no main effect or interaction of group and
time on climbing or immobility (all P > 0.19) (see Figure
3). The interaction of group and time on swimming
approached significance (F4,42 =2 . 4 8 ,P = 0.06). The
three groups did not differ in latency to immobility (P =
0.72, data not shown). To explore the possibility that
group differences were masked by low power by inclu-
sion of several timepoints in the analysis (shorter times
than 15 min have been used for analysis by others, for
example [29]), a multivariate analysis of variance (MAN-
OVA) was computed for climbing, immobility, and
swimming, using only the first 5 min in the FST. The
multivariate test of group was significant (Pillai’st r a c e
F6,40 =2 . 7 3 ,P = 0.025), with significant between subject
effects for immobility (F2,21 = 4.32, P = 0.027) and for
swimming (F2,21 = 6.78, P = 0.005). Post hoc analyses
indicated that CORT rats spent less time immobile and
more time swimming than did NO-INJ rats and more
time swimming than VEHIC rats (all P < 0.05) (see Fig-
ure 3).
Thus, the effects of treatment were limited to the first
5 min of the test and were in the opposite direction
than predicted. The measure of depressive behavior in
the FST is immobility, and thus CORT rats showed less
depressive behavior than did NO-INJ rats. The VEHIC
rats’ behavior fell between that of the CORT and NO-
INJ rats. An alternative explanation is that the increased
swimming and decreased immobility of CORT rats is a
reflection of their increased anxiety evident in the EPM.
Anxiety symptoms are as common as depressed mood is
among people meeting the criteria for major depressive
disorder [50], and there is evidence that anxiety may be
a precursor for the development of depression [51].
Nevertheless, there is increasing evidence of both shared
and distinct neural mechanisms underlying anxiety and
depressive behaviors (for example, [52]).
Others also have reported the apparent contradiction
of increased anxiety and decreased depressive behaviors
in animal models. For example, knockout (KO) mice for
the 5-hydroxytryptamine (5HT)1A receptor also exhib-
ited increased anxiety in an open field test and increased
swimming and decreased immobility in the FST [53].
The authors interpreted the behavior in the FST as
further evidence of increased anxiety and emotional
reactivity rather than to decreased depression, and they
suggested the differences in KO mice might involve
increased serotonergic turnover. More recently, KO
mice of the 5HT1A autoreceptor had increased anxiety
and did not differ from controls in the FST, whereas
KO mice of the 5HT1A heteroreceptor had increased
immobility in the FST and did not differ in anxiety from
controls [52]. In adults, chronic injection of corticoster-
one decreases neural responsiveness to serotonin (for
example, [54]) and increases depressive behavior in the
Figure 3 Mean (SEM) of the behavioral measures for the forced
swim test (FST) for corticosterone injected (CORT), vehicle
injected (VEHIC) and no injection (NO-INJ) groups. Matched
letters indicate significant (P < 0.05) differences between groups
within each behavioral measure.
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difference in the results of the previous studies in adults
whereby injection of corticosterone increased depressive
behavior compared to our finding of reduced depressive
behavior (or increased anxiety) for adolescents is that
our study involved fewer injections than those in studies
of adults (16 versus 21 injections). A stronger possibility
is that the differences between the studies of adults and
ours with adolescents are because of developmental dif-
ferences in susceptibility to the effects of stress/corticos-
terone. Studies of adults have found more robust
differences between vehicle injected and corticosterone
injected groups, thus adults may be less susceptible to
injection stress than are adolescents. The ongoing
maturation of neural circuitry underlying emotional
behavior, which is evident, for example, in the different
responses of adolescent and adult rats to selective sero-
tonin reuptake inhibitors (for example, [55]), may render
the circuitry more vulnerable.
In experiment 2, we eliminated the possibility of stress
of injection by administering corticosterone in the
drinking water. The method, which involves dissolving
corticosterone in ethanol, was based on established pro-
cedures that have effectively mimicked many of the
effects of chronic stress in adult rats (for example,
[31-33]). Because the comparable studies available were
conducted only in adults, we were concerned that etha-
nol alone may have an effect in adolescents. Thus, two
control groups were used, one group was given 2.5%
ethanol to drink and the other was given water only. To
better assess the specificity of effects to developmental
stage, an additional three experimental groups received
treatment in adulthood.
Experiment 2
Weight
There were no group differences in weight on postnatal
day 30 (F1,17 = 0.54, P = 0.93), but by the 16th day of
treatment on postnatal day 45, CORT-ETOH rats had
gained less weight than ETOH and WATER rats, which
did not differ (F1,17 =4 . 3 7 ,P = 0.029, see Figure 4).
There were no weight differences for the adult groups
on the first day of treatment (F1,17 = 2.84, P = 0.09), but
by the 16th day of treatment, CORT-ETOH rats had
gained less weight than ETOH and WATER rats, which
did not differ (F1,17 = 13.85, P < 0.0001, see Figure 4).
Thus, the effects of corticosterone treatment in the
drinking water were similar to the results in other stu-
dies (for example, [31,56]) and to the effect of corticos-
terone injection in experiment 1, and the effects were
comparable for adolescents and adults. No effect of 2.5%
ethanol was observed on weight.
Intake
Treatment altered the intake of the three groups differ-
ently for adolescents than for adults. For adolescents,
there was an interaction of treatment day and group
(F2,14 = 3.25, P = 0.04): The intake of CORT-ETOH rats
w a sl e s st h a nt h a to fE T O Hr a t s( P = 0.01) and less
than that of WATER rats on day 16 of treatment (P <
0.0001) (see Figure 5a). For adults, although the intake
of CORT-ETOH rats was less than that of the other
groups, only the effect of treatment day was significant
(F2,14 = 6.42, P = 0.01), whereby intake increased over
days (see Figure 5b). Thus for adults, there seemed to
be an immediate aversion to corticosterone that reduced
intake throughout, whereas in adolescents, corticoster-
one did not reduce drinking initially. The reduced
Figure 4 Mean (SEM) weight at postnatal day 45 the last day of treatment for rats ingesting corticosterone dissolved in 2.5% ethanol
(CORT-ETOH), 2.5% ethanol (ETOH), or water (WATER). The lighter colored portion of the column represents weight at postnatal day 30, the
first day of treatment, and the darker colored portion of the column represents weight gain during the 16 days of treatment. Matched letters
indicate significant (P < 0.05) differences between groups in weight gain for adolescent and for adult groups.
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be related to their reduced body weight or to an aver-
sion that was slower to develop. For neither age group
was the intake of rats drinking 2.5% ethanol different
from those rats drinking water only.
The interaction of treatment day and age was signifi-
cant for the dose of ethanol consumed (ml/kg) (F2,14 =
15.99, P < 0.0001): For adolescents, the dose of ethanol
consumed (ml/kg) decreased over treatment days (F2,10
= 84.95, P < 0.0001) similarly for the CORT-ETOH and
ETOH rats (see Figure 5c). For adults, there was no
effect of, or interaction of, treatment day and group.
The higher dose of ethanol ingested by adolescents than
by adults was significant only at treatment day 2 and 8
(both P < 0.0001). The interaction of age × treatment
day was significant for the dose of corticosterone (mg/
kg) consumed by the CORT-ETOH groups (F2,14 = 6.42,
P = 0.01): For adolescents, the dose of corticosterone
(mg/kg) consumed by the CORT-ETOH rats declined
over time (F2,6 = 309.3, P < 0.0001), and for adults (F2,6
= 91.5, P < 0.0001), the dose of corticosterone (mg/kg)
consumed increased over time (see Figure 5d). The
higher dose of corticosterone ingested by adolescents
than by adults was significant only at treatment day 2 (P
= 0.02). These results highlight the difficulty in adminis-
tering comparable dosages in drinking water to rats of
different stages of development.
EPM and FST
There were no differences among the groups for any of
the EPM measures for either adolescents (all P > 0.32)
or adults (all P > 0.13). Adolescents spent less time in
the center hub than did adults, but no other age differ-
ence was significant (F1,34 =4 . 2 6 ,P = 0.047) (see Figure
6). Although there was effect of time for the FST mea-
sures, with climbing and swimming decreasing and
immobility increasing with time for both age groups
(see Figure 7), the only effect of group was a group ×
time interaction (F6,51 = 2.63, P = 0.027) for time spent
climbing by adults. No group comparison, however, was
significant at any timepoint.
There are several possibilities for the lack of an effect
of corticosterone treatment on anxiety-like and depres-
sive behavior when administered in the drinking water
compared to when injected. One possibility is that we
would have uncovered behavioral differences among the
groups using a broader range of tests of anxiety-like and
Figure 5 Mean (SEM) intake of fluid in grams in 2 days per pair of rats during 16 days of treatment for rats ingesting corticosterone
dissolved in 2.5% ethanol (CORT-ETOH), 2.5% ethanol (ETOH), or water (WATER) as adolescents (a) or as adults (b). (c) Shows the dose
of ethanol consumed by body weight and (d) provides the dose of corticosterone consumed by body weight. Matched letters indicate
significant (P < 0.05) differences between groups on a treatment day. The main effect of treatment day was significant in (b), in (c) for
adolescents only, and in (d) for both adolescents and adults, although in opposite directions (all P < 0.05).
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in adolescence, corticosterone is not as effective at alter-
ing emotional behavior in the absence of actual stressful
experiences, such as injection. Of note, in experiment 1,
the effect of injection of corticosterone on behavior was
only marginally greater than that of injection of vehicle.
Exogenous corticosterone and chronic stress do not
always have the same effects when directly compared.
Although both 21 days of 400 μg/ml corticosterone in
drinking water and 21 days of chronic stress (restraint 6
h/day) caused retraction of hippocampal dendrites, only
chronic stress impaired spatial memory [57], and the
two manipulations differed in their effects on fear condi-
tioning [33] and had the opposite effects on proteins
involved in synaptic plasticity in the piriform cortex
[58]. Whereas 21 days of injection of corticosterone
decreased the number of cells expressing reelin in the
hippocampus, 21 days of daily restraint did not [59].
Nevertheless, the differential effects of chronic stress
versus exogenous administration of corticosterone do
not explain the absence of an effect of corticosterone
observed in experiment 2.
Another possibility is that 16 days is insufficient to
have an effect with 400 μg/ml in the drinking water,
especially when the pharmacokinetics of this method of
delivery differs from a bolus injection, which is more
similar to that produced by a bout of restraint. Consis-
tent with the possibility that dose may be a factor is
that injections of 10 mg/kg corticosterone in adult rats
are sufficient to cause dendritic retraction in the hippo-
campus (for example, [60,61]) but higher doses are
required to increase depressive behavior in the FST [28].
Lastly, the evidence for an effect of corticosterone deliv-
ered in the drinking water on anxiety and depressive
behavior is not as substantial as it is for corticosterone
delivered by injection. The available studies used mice
rather than rats and lower doses (<50 μg/ml) and found
reduced depressive behavior when provided for 1 to 4
days [62], increased depressive behavior when provided
for 14 days and tested 2 weeks later [63], but did not
affect depressive behavior in the FST when provided for
4 weeks [64]. Thus, given the advantages of administer-
ing corticosterone in the drinking water (for example,
no handling or injection of the animals is involved), it
would be worthwhile to test the effects of the 400 μg/ml
dose provided over a longer time frame on behavior.
Plasma corticosterone
Baseline samples were not collected before the FST to
prevent interference with subsequent behavior. Plasma
concentrations of corticosterone obtained at timepoints
after the FST indicated that both corticosterone treat-
ment and the 2.5% ethanol vehicle altered HPA func-
tion. For adolescents, the interaction of sampling time
and group was significant (F4,34 = 5.73, P = 0.001) (see
Figure 8). At removal from the FST and 45 min later,
CORT-ETOH rats had lower corticosterone concentra-
tions than had WATER rats (both P < 0.0001). ETOH
rats had lower corticosterone concentrations than had
WATER rats only immediately after removal from the
FST (P = 0.001). Group differences were not significant
90 min after the FST.
For adults, the interaction of sampling time and group
was significant (F4,34 =1 6 . 5 5 ,P < 0.0001) (see Figure 8).
On removal from the FST and 45 min later, CORT-
ETOH rats had lower corticosterone concentrations
than had ETOH (both P < 0.0001) and WATER rats
(both P < 0.01), and ETOH rats had higher corticoster-
one concentrations than had WATER rats (both P <
0.05). The groups did not differ 90 min after the FST.
Reduced adrenal function after lengthy exogenous
treatment with high doses of corticosterone is a typical
finding, because of the reduction in size of the adrenal
gland caused by exogenous corticosterone, which is in
contrast to the increase in size of the adrenal produced
by chronic stress (for example, [28,31]). Thus, the lack
of effect of treatment on behavior cannot be attributed
Figure 6 Mean (SEM) of the behavioral measures for the
elevated plus maze (EPM) for rats ingesting corticosterone
dissolved in 2.5% ethanol (CORT-ETOH), 2.5% ethanol (ETOH),
or water (WATER) as adolescents (upper panel) or as adults
(lower panel). Matched letters indicate significant (P < 0.05)
differences between treatment groups for each behavioral measure
within each age group.
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ethanol vehicle on corticosterone release was unex-
pected, as most studies of corticosterone in the drinking
water have not included a ‘no 2.5% ethanol’ control
group (for example, [33,56,58,65]). In adolescents, the
low dose of ethanol in the drinking water reduced corti-
costerone release after the FST, but not to the same
extent that corticosterone and ethanol combined did. In
adults, ethanol prolonged corticosterone release after
the FST. Whether the effect of ethanol involved effects
on the adrenal gland or at a higher level of control of
the HPA axis in either adolescents or adults is
unknown. After acute or chronic ethanol exposure to
adult rodents, usually heightened HPA function is
reported, with changes evident at all levels of the HPA
axis (such as increased adrenal weight/corticosterone
content, higher expression of pituitary pro-opiomelano-
cortin (POMC) mRNA, of hypothalamic corticotropin-
releasing hormone (CRH) mRNA) that are consistent
with higher stress-induced corticosterone release (for
Figure 7 Mean (SEM) of the behavioral measures for the behavioral measures for the forced swim test (FST) for rats ingesting
corticosterone dissolved in 2.5% ethanol (CORT-ETOH), 2.5% ethanol (ETOH), or water (WATER) as adolescents (left panels) or as
adults (right panels).
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HPA function after alcohol exposure, see [71]).
The differences in the effects of ethanol in the two age
groups may reflect differences in their developmental
stage (for example, [72]) or that the dose of ethanol
consumed was higher for adolescents than for adults. In
adults, although activation of the HPA axis was found
to a first dose of alcohol, self-administration or experi-
menter administration of alcohol was found to dampen
HPA responses to subsequent stressors up to 24 days
after removal of the alcohol (reviewed in [71]). One
study of adolescent exposure to ethanol (alcohol vapors)
found evidence of reduced HPA function when tested in
adults [73]. In contrast, binge drinking (3 g/kg/day)
beginning at postnatal day 37 increased the expression
of secretagogues of ACTH in the paraventricular
nucleus of the hypothalamus in adolescence [74]. Such
studies, however, involved much higher doses than used
here (for example, a bolus injection of 4.5 mg/kg to a
rat is far more than the 200 mg/kg highest dose
Figure 8 Mean (SEM) concentrations of corticosterone at timepoints after removal from the forced swim test (FST) for rats ingesting
corticosterone dissolved in 2.5% ethanol (CORT-ETOH), 2.5% ethanol (ETOH), or water (WATER) as adolescents (upper panel) or as
adults (lower panel). Matched letters indicate significant (P < 0.05) differences between treatment groups at a timepoint within each age
group.
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present study). Nevertheless, the present results suggest
that a no vehicle control group should be used in future
studies using ethanol as a vehicle for corticosterone.
Conclusions
Administration of exogenous corticosterone has proven
to be an effective preclinical model of depression in
adult rodents to study the relationships among stress,
glucocorticoids, and depression (reviewed in [14]). The
findings of the present experiments suggest there are
challenges to overcome in the use of exogenous corti-
costerone to investigate the heightened vulnerability of
adolescents to stressors. First, the stress of injection
masks potential effects of exogenous corticosterone in
adolescents, whereas robust differences between vehicle-
injected and corticosterone-injected subjects are found
routinely in adults [14]. Second, corticosterone delivered
in the drinking water does not allow for sufficient con-
trol of dosing for comparable treatment in adolescents
and adults. Administration procedures that do not
involve ethanol, such as the use of corticosterone hemi-
succinate rather than corticosterone, are recommended,
because even the low dose of ethanol used here affected
corticosterone release in both adolescents and adults.
Further, although the dose of corticosterone used (400
μg/ml) represents the high end of doses administered in
such a way, 16 days of treatment did not produce effects
on behavior in the EPM and the FST, although many
studies have found chronic stress in adolescence to
affect behavior in the EPM and the FST within shorter
timeframes (reviewed in [13]). Thus, although this route
of administration overcomes the problem of stress of
injection, the more sustained pattern of corticosterone
exposure through such oral administration may not
allow for marked effects on mood-related behavior to be
observed in rats. In sum, the present results highlight
challenges to overcome in the use of exogenous corti-
costerone treatments in animal models to study sensitiv-
ity to stress and mood disorders in adolescence.
Clinicians have long recognized there are unique fea-
tures to mood disorders in adolescence compared to in
adulthood, irrespective of whether or not a mood disor-
der is the same fundamental disease at each age (for
example, [75]). In humans, anxiety is primarily a disor-
der of childhood and adolescence, with anxiety in adults
stemming from adolescence, and stress is a risk factor
for anxiety in adolescence [76,77]. Immaturity of the
relevant regulatory mechanisms in adolescence is
thought to underlie the difference in performance on
behavioral tests of anxiety of adolescent and adult rats
[78,79]. In experiment 1, injected and corticosterone-
treated adolescents had increased anxiety-like behavior
compared to control rats, with little difference observed
in depressive behavior. Similar treatments in adult rats
found greater increases in depressive behavior than in
anxiety [14]. These results suggest there are age differ-
ences in the behavioral expression of exposure to corti-
costerone that may parallel the developmental stage-
specific manifestations of mood disorders in humans. In
humans, the age of onset for depression is later than for
anxiety, which also suggests that the maturation of rele-
vant neural circuitries may determine which mood dis-
order or symptom is evident at each age. These points
underscore the relevance of animal models for under-
standing the pathogenesis of mood disorders and the
importance of investigating the range of developmental
stages in both preclinical and clinical studies.
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